Myriad Genetics, Inc. Enhances Drug Discovery and Development Capability
Mark B. Anderson, Ph.D. and Robert O. Carlson, Ph.D. Head Departments
SALT LAKE CITY, Oct. 26 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc.
(Nasdaq: MYGN) has named Mark Anderson, Ph.D., as Vice President, Chemistry
and Robert Carlson, Ph.D., as Vice President, Discovery Biology for Myriad
Pharmaceuticals, Inc.
Dr. Anderson oversees all aspects of chemistry at Myriad Pharmaceuticals,
including medicinal, analytical and hit-to-lead chemistries, as well as
compound characterization and analysis. He joined Myriad from Elitra
Pharmaceuticals where he was Director of Medicinal Chemistry, and oversaw
microbiology and ADMET efforts, focused on the development of drug candidates
for drug-resistant bacterial and fungal infections. Previously, Dr. Anderson
was with Pfizer's La Jolla Laboratories as Associate Director of Medicinal
Chemistry. At Pfizer, he was designing small molecules for potential use in
hormone-dependent cancers, kinase targets and new antivirals.
Dr. Carlson oversees all biological components of drug discovery,
including in vivo and in vitro pharmacology, high-throughput screening and
target validation, in his new role with Myriad Pharmaceuticals. He joined
Myriad from Karo Bio USA, a pharmaceutical company specializing in hormone
receptor discovery, where he was Director of Research, supervising a broad-
based team of discovery scientists. Previously, Dr. Carlson was with Bayer
Corporation as a Senior Research Scientist in Cancer discovery, responsible
for all aspects from high-throughput screening through in-vivo proof of
principle.
"It is my pleasure to welcome Drs. Anderson and Carlson to Myriad," said
Adrian Hobden, Ph.D., President of Myriad Pharmaceuticals, Inc. "They have
invaluable experience in areas of strategic interest to Myriad along with the
proven ability to get actionable results from complex data, which are required
to move forward aggressively with promising compounds."
Dr. Anderson received his B.S. degree in Chemistry from the University of
Minnesota. He earned his Ph.D. from Purdue University in Chemistry and
completed his postdoctoral fellowship at Harvard University, focusing on the
synthesis of novel bioisosteres of Palytoxin. Dr. Anderson is the inventor of
numerous patented technologies, the author of dozens of scientific articles
and a frequent invited lecturer.
Dr. Carlson received his B.S. degree in Natural Sciences from the
University of Wisconsin, and earned his Ph.D. in Biochemistry from Brandeis
University. He completed post-doctoral fellowships in the Department of
Biochemistry and Molecular Biology at Georgetown University and with the
Mental Health Research Institute at The University of Michigan Medical School.
Dr. Carlson has numerous peer-reviewed scientific articles to his credit, in
addition to book chapters on biochemical topics and has been an invited expert
lecturer on various aspects of drug discovery.
Myriad Genetics, Inc. is a biopharmaceutical company focused on the
development of novel healthcare products. The Company develops and markets
predictive medicine products, and is developing and intends to market
therapeutic products. Myriad's news and other information are available on
the Company's Web site at www.myriad.com.
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. These
forward looking statements are based on management's current expectation and
are subject to certain risks and uncertainties that could cause actual results
to differ materially from those set forth or implied by forward-looking
statements. These include, but are not limited to, uncertainties as to the
extent of future government regulation of Myriad Genetics' business;
uncertainties as to whether Myriad Genetics and its collaborators will be
successful in developing, and obtaining regulatory approval for, and
commercial acceptance of, therapeutic compounds; the risk that markets will
not exist for therapeutic compounds that Myriad Genetics develops or if such
markets exist, that Myriad Genetics will not be able to sell compounds, which
it develops, at acceptable prices; and the risk that the Company will not be
able to sustain revenue growth for its predictive medicine business and
products. These and other risks are identified in the Company's filings with
the Securities and Exchange Commission, including the Company's Annual Report
on Form 10-K for the fiscal year ended June 30, 2004. All information in this
press release is as of October 26, 2004, and Myriad undertakes no duty to
update this information unless required by law.
SOURCE Myriad Genetics, Inc
.
10/26/2004
CONTACT: William A. Hockett, Vice President of Corporate Communications,
Myriad Genetics, Inc., +1-801-584-3600
Web site: http://www.myriad.com
|
